Stock SUVEN SUVEN LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Suven Life Sciences Limited NSE India S.E.

Equities

SUVEN

INE495B01038

Biotechnology & Medical Research

Market Closed - NSE India S.E.
Other stock markets
 09:03:24 2024-04-25 am EDT 		5-day change 1st Jan Change
113.6 INR +1.02% Intraday chart for Suven Life Sciences Limited +3.27% +40.68%
Apr. 15 Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA CI
Feb. 06 Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA CI

Business Summary

Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.

Number of employees: 132

Sales per Business

INR in Million2022Weight2023Weight Delta
Research and Development Services
100.0 %
118 100.0 % 135 100.0 % +14.31%

Sales per region

INR in Million2022Weight2023Weight Delta
India
62.0 %
63 53.2 % 84 62.0 % +33.24%
United States
28.5 %
44 37.5 % 39 28.5 % -13.26%
Rest of the World
8.0 %
10 8.1 % 11 8.0 % +13.00%
Europe
1.5 %
1 1.2 % 2 1.5 % +46.76%

Managers

Managers TitleAgeSince
Venkateswarlu Jasti CEO
 Chief Executive Officer 74 89-03-08
M. Mohan Kumar DFI
 Director of Finance/CFO - 20-01-09
Shrenik Soni CMP
 Compliance Officer - 20-01-09
C. Rajendiran CTO
 Chief Tech/Sci/R&D Officer 63 01-12-31
P. Lakshmana Rao PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Venkateswarlu Jasti CEO
 Chief Executive Officer 74 89-03-08
Sudha Rani Jasti FOU
 Founder 70 89-03-08
Syed Ehtesham Hasnain BRD
 Director/Board Member 70 10-04-29
Santanu Mukherjee BRD
 Director/Board Member 67 18-05-14
Sambasiva Rao Vajja BRD
 Director/Board Member 71 Jan. 29
J. A. S. Padmaja BRD
 Director/Board Member 62 18-11-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 218,073,717 63,135,411 ( 28.95 %) 0 28.95 %

Shareholders

NameEquities%Valuation
Jasti Family
69.56 %
151,697,500 69.56 % 181 M ₹
Rambabu Chirumamilla
1.376 %
3,000,000 1.376 % 4 M ₹
quant Money Managers Ltd.
1.046 %
2,280,000 1.046 % 3 M ₹
Sattva Organisers LLP
1.020 %
2,225,000 1.020 % 3 M ₹
Government of India
0.1067 %
232,605 0.1067 % 278 058 ₹
Pension Reserves Investment Management Board
0.0164 %
35,678 0.0164 % 42 650 ₹
Hamon Asset Management Ltd.
0.009953 %
21,704 0.009953 % 25 945 ₹
Motilal Oswal Asset Management Co. Ltd.
0.000390 %
850 0.000390 % 1 016 ₹
Goldman Sachs Asset Management (India) Pvt Ltd.
0.000317 %
692 0.000317 % 827 ₹

Company contact information

Suven Life Sciences Ltd.

6th Floor, SDE Serene Chambers Avenue - 7, Road No. 5

500034, Hyderabad

+91 40 2354 1142

http://www.suven.com
address Suven Life Sciences Limited(SUVEN)

Group companies

NameCategory and Sector
SUVEN PHARMACEUTICALS LIMITED
Industrial Conglomerates

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.71% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+5.83% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+44.98% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.15% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.16% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.87% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+24.98% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.07% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SUVEN Stock
  4. SUVEN Stock
  5. Company Suven Life Sciences Limited